MyMeds&Me Announce Collaboration with Oracle Health Sciences
London, UK, 25 March, 2015: MyMeds&Me, a leading SaaS provider of web-based adverse event and product quality capture solutions for life sciences, today announced their collaboration with Oracle Health Sciences to provide the Reportum® solution to Oracle Argus safety customers.
This collaboration allows access to the innovative Reportum® solution providing a standardised method of capturing complete Adverse Event data at source, from all reporter types. The Reportum® solution provides simple, web-based, user-friendly safety data capture at initial reporter interaction and supports direct reporting by consumers - streamlining what is often a paper-based activity that generates duplicate data entry processes, call centres - often dealing with high volumes of contacts with varying levels of experience and healthcare professionals.
For Oracle customers, the Oracle Argus pharmacovigilance platform will provide the hub for all safety and product quality data captured via the Reportum® solution. They will be able to review, manage, analyse and report all safety and product quality data consistently, irrespective of reporting route.
This combined solution will enable life science companies with Adverse Event obligations to: o Increase pharmacovigilance efficiency and reduce cost
o Deliver complete, cleaner data to regulators, faster
o Improve understanding of benefit risk profiles for pharmaceutical products
Dr. Andrew Rut, CEO at MyMeds&Me comments, “The recent ISMP report1 highlighted the scale of the issue of non-complete AE data submitted to the FDA. We believe the collaboration with Oracle Health Sciences delivers innovation to Oracle Argus Safety customers who will benefit from rapid access to complete and cleaner safety data, irrespective of reporter route, by implementing the Reportum® solution”.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
